Earnings summaries and quarterly performance for BioCorRx.
Research analysts covering BioCorRx.
Recent press releases and 8-K filings for BICX.
BioCorRx CEO to Present at Investor Forum, Reports Strong Q3 2025 Revenue Growth
BICX
Earnings
Revenue Acceleration/Inflection
M&A
- BioCorRx Inc. CEO, Lourdes Felix, is scheduled to present live at the Life Sciences Virtual Investor Forum on December 11th at 2:30 PM ET.
- The company reported Q3 2025 revenue of $635,224, a significant increase from $0 in Q3 2024, and a reduced net loss of $808,502 compared to $1.5 million in Q3 2024.
- BioCorRx also delivered strong 1H 2025 revenue growth of 3,985% to $313,000, with Q2 2025 revenue growing 4,306% to $178,000, primarily driven by LUCEMYRA® sales.
- The company recently acquired LUCEMYRA® (lofexidine), an FDA-approved, non-opioid medication indicated to mitigate opioid withdrawal symptoms, adding a commercial product to its portfolio.
Dec 10, 2025, 1:35 PM
Quarterly earnings call transcripts for BioCorRx.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more